Can you believe it? Even Ben and Jerry’s is looking into developing a CBD product! And so is Coca Cola, which long ago began diversifying out of carbonated sugar water. The enormous popularity of CBD in the consumer market has also led to many medical claims, some of which could be unfounded, which is why we stay away from making those kinds of claims for our products, even though we know anecdotally how our products work.

There is a reason we are careful about the medical claims we make for CBD. In fact we make none. That’s because the government has made it almost impossible to study the medical effects of CBD the way other promising drugs have been studied. Even researchers who work in the field can never tell what kind of  CBD supply they will get from the government, which until recently still controlled the CBD used for medical research projects. Some scientists have said that they get low grade CBD when they get it from the sources they are supposed to get it from, which is often government agencies that have confiscated it. It’s an all-around unsatisfactory, situation, made worse because of the continued illegality of THC, which also comes from the marijuana plant, in some states.

 

All this will change in the United States this year because hemp has been made legal. But it takes more than a year to do double-blind placebo-controlled clinical trials that can get CBD through the FDA approval process. And who will pay for them? Cannabidiol itself can’t be patented, and that’s a major disincentive.

 

According to Zoe Cormier

Raphael Mechoulam, a professor at the Hebrew University of Jerusalem in Israel, has spent his career studying cannabinoids. In 1963, he isolated CBD, and a year later THC. His own research has indicated that CBD would be helpful for arthritis, Type 1 diabetes, heart disease, graft-versus-host disease, and even psychosis. But many other possible treatments remain theoretical, because they rely on funding for expensive medical trials. 

   Mechoulam discovered the anti-convulsant properties of CBD, giving the molecule to a handful of epileptic and non-epileptic patients in a double-blind study published in 1980. ‘It took another 35 years until another clinical trial was conducted. We shouldn’t have waited so long,’ he says. ‘Clinical trials cost millions, and the chances are that if there is no patent, drug companies will just not be interested.’

Lab tests on animals and cell cultures have so far found that CBD can protect cells from oxidative stress and ameliorate anxiety in rats. It even demonstrates anti-cancer properties in vitro. Yet promising lab studies based on nonhuman subjects are not sufficient to prove the same benefits in people.

 

That’s why even doctors who have heard rave reviews from their patients about discomfort relief or anxiety relief are still reluctant to prescribe it. They still have no idea of the proper dosing of CBD for the ailments people say it helps. The patients know better.

 

Drug interactions are another open issue. We already know CBD slows down the metabolism of enzymes in the liver, which means if you are taking certain immunotherapy drugs for cancer treatment,  CBD could make those less effective. 

All this being said there is a huge amount of research being done to support the anecdotal experience of users who have tried CBD for everything from anxiety to insomnia with great results. And we have many customers who are healthy adults who use our tincture to help them calm down or fall asleep at night.

 

We can promise you that we’re committed to presenting our customers with the latest and best information. Stay tuned.